Company profile: InteKrin Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage biopharmaceutical development and commercialization of breakthrough therapeutics targeting neuroendocrine, metabolic, and immune disorders, addressing diseases such as diabetes, metabolic syndrome, and cancer.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to InteKrin Therapeutics
Genfit
HQ: France
Website
- Description: Provider of innovative therapeutic and diagnostic solutions for metabolic and liver-related diseases, dedicated to discovery and development in areas with considerable unmet medical needs where approved treatments are lacking; a late-stage biopharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genfit company profile →
Sigilon Therapeutics
HQ: United States
Website
- Description: Provider of immune-privileged, immune-protected engineered human cell products to treat acute and chronic diseases by restoring normal physiology while aiming to avoid fibrosis and immune rejection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sigilon Therapeutics company profile →
Inversago Pharma
HQ: Canada
Website
- Description: Provider of clinical-stage biotech therapies based on peripherally-acting CB1 inverse agonists, including INV-202, a small molecule CB1 receptor blocker for metabolic disorders in Phase 2 studies for diabetic kidney disease and obesity, and INV-347, a next-generation oral CB1 receptor blocker in Phase 1 evaluating safety, tolerability, and pharmacokinetics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inversago Pharma company profile →
GRI Bio
HQ: United States
Website
- Description: Provider of therapies for inflammatory and autoimmune diseases, including GRI-0621, an oral inhibitor of iNKT cell activity for idiopathic pulmonary fibrosis, and GRI-0803, a novel activator of human type 2 NKT cells for autoimmune disorders with an initial focus on systemic lupus erythematosus, supported by a proprietary library of over 500 compounds.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GRI Bio company profile →
Liminal Biosciences
HQ: Canada
Website
- Description: Provider of state-of-the-art bio-separation technologies and therapeutic programs, including LMNL6511, a selective GPR84 antagonist for inflammatory and fibrotic diseases expected to enter Phase 1 clinical trials; an OXER1 antagonist in preclinical for eosinophilic-driven diseases (asthma, atopic dermatitis); and a discovery-stage liver-safe GPR40 agonist for type 2 diabetes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Liminal Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for InteKrin Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to InteKrin Therapeutics
2.2 - Growth funds investing in similar companies to InteKrin Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for InteKrin Therapeutics
4.2 - Public trading comparable groups for InteKrin Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →